Sandoz And Polpharma Strike Global Deal For Natalizumab
Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.
You may also be interested in...
Celebrating a “major milestone in the biosimilar clinical development programs,” Gan & Lee has just presented positive data at the recent at the Scientific Sessions of the American Diabetes Association.
Sandoz plans to add at least one new molecule per year to its biosimilar development plans, while still maintaining a “selective” approach to targets, head of biopharmaceuticals Pierre Bourdage explains in the second part of an exclusive interview with Generics Bulletin.
Poland’s Polpharma SA has absorbed subsidiaries Polpharma BH and Medana Pharma as part of the group’s efforts to simplify management structures and processes and increase operational efficiency.